A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters

We previously described a nasally delivered monovalent adenoviral-vectored SARS-CoV-2 vaccine (ChAd-SARS-CoV-2-S, targeting Wuhan-1 spike [S]; iNCOVACC(®)) that is currently used in India as a primary or booster immunization. Here, we updated the mucosal vaccine for Omicron variants by creating ChAd...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Baoling, Darling, Tamarand L., Desai, Pritesh, Liang, Chieh-Yu, Dmitriev, Igor P., Soudani, Nadia, Bricker, Traci, Kashentseva, Elena A., Harastani, Houda, Schmidt, Aaron G., Curiel, David T., Boon, Adrianus C.M., Diamond, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187308/
https://www.ncbi.nlm.nih.gov/pubmed/37205450
http://dx.doi.org/10.1101/2023.05.04.539332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187308/
https://www.ncbi.nlm.nih.gov/pubmed/37205450
http://dx.doi.org/10.1101/2023.05.04.539332

Ejemplares similares